On Wednesday, Following Stocks were among the “Top Priority Stocks” For Traders – Peregrine Pharmaceuticals (NASDAQ:PPHM), Cerus Corporation (NASDAQ:CERS), Galena Biopharma Inc (NASDAQ:GALE)
Peregrine Pharmaceuticals (NASDAQ:PPHM), declined -4.76%, and closed at $1.40. The company has the market capitalization of $276.85M. The beta value of the stock is 1.42. On the other hand the stock’s volatility for the week is 5.82 %, and for the month is 7.51%. The stock’s price to book ratio is 11.03, however price to sale ratio is 5.19. Analyst’s mean recommendation regarding this stock is 2.00. (where 1=Buy, 5=Sale).
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer together with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also evaluating its lead molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of various solid tumor types. In addition, it provides contract manufacturing services ranging from cell line development to commercial current good manufacturing practice biomanufacturing to third-party clients.
Cerus Corporation (NASDAQ:CERS), dipped -4.74%, and closed at $4.02. The stock has price to sale ratio of 10.51, however, price to book ratio is 7.58. With recent decline, the year-to-date (YTD) performance reflected a -35.58 % decline above last year. During the past month the stocks lose -26.37%, bringing three-month performance to -40.62% and six-month performance to 3.08%. The mean recommendation of analysts for this stock is 1.50. (where 1=Buy, 5=Sale).
Cerus Corporation operates as a biomedical products company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, counting viruses, bacteria, and parasites, in addition to potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.
Galena Biopharma Inc (NASDAQ:GALE), dropped -4.41%, and closed at $1.41. The stock volatility for the week is 5.23%, while for the month remained 6.37%. The company holds consensus target price of $5.14.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.31 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 63.50% and Annual EPS growth for the past 5 years is considered as 24.20%.
The mean recommendation of analysts for this stock is 2.40. (where 1=Buy, 5=Sale).
Fura Emeralds Inc., a natural resource company, attains and explores mineral properties in Canada and internationally. It has a 51% interest in the Iron Horse Property that comprises of 7 mining tenures covering an area of 1,915 hectares and is located in Skeena and Liard Mining Divisions, British Columbia, Canada. The company was formerly known as Wolf Resource Development Corp. and changed its name to Fura Emeralds Inc. in March 2015. Fura Emeralds Inc. was incorporated in 2006 and is based in Toronto, Canada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
